Toderici Mara, de la Morena-Barrio María Eugenia, Padilla José, Miñano Antonia, Antón Ana Isabel, Iniesta Juan Antonio, Herranz María Teresa, Fernández Nuria, Vicente Vicente, Corral Javier
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain.
Servicio de Neurología, Hospital Universitario Reina Sofía, Murcia, Spain.
PLoS One. 2016 Mar 22;11(3):e0152159. doi: 10.1371/journal.pone.0152159. eCollection 2016.
Antithrombin is a crucial anticoagulant serpin whose even moderate deficiency significantly increases the risk of thrombosis. Most cases with antithrombin deficiency carried genetic defects affecting exons or flanking regions of SERPINC1.We aimed to identify regulatory mutations inSERPINC1 through sequencing the promoter, intron 1 and 2 of this gene in 23 patients with antithrombin deficiency but without known genetic defects. Three cases with moderate antithrombin deficiency (63-78%) carried potential regulatory mutations. One located 200 bp before the initiation ATG and two in intron 1. These mutations disrupted two out of five potential vitamin D receptor elements (VDRE) identified in SERPINC1 with different software. One genetic defect, c.42-1060_-1057dupTTGA, was a new low prevalent polymorphism (MAF: 0.01) with functional consequences on plasma antithrombin levels. The relevance of the vitamin D pathway on the regulation of SERPINC1 was confirmed in a cell model. Incubation of HepG2 with paricalcitol, a vitamin D analog, increased dose-dependently the levels of SERPINC1transcripts and antithrombin released to the conditioned medium. This study shows further evidence of the transcriptional regulation of SERPINC1 by vitamin D and first describes the functional and pathological relevance of mutations affecting VDRE of this gene. Our study opens new perspectives in the search of new genetic defects involved in antithrombin deficiency and the risk of thrombosis as well as in the design of new antithrombotic treatments.
抗凝血酶是一种关键的抗凝丝氨酸蛋白酶抑制剂,即使是中度缺乏也会显著增加血栓形成的风险。大多数抗凝血酶缺乏病例携带影响SERPINC1外显子或侧翼区域的基因缺陷。我们旨在通过对23例抗凝血酶缺乏但无已知基因缺陷患者的该基因启动子、内含子1和2进行测序,来鉴定SERPINC1中的调控突变。3例中度抗凝血酶缺乏(63%-78%)患者携带潜在的调控突变。一个位于起始ATG前200 bp处,另外两个位于内含子1中。这些突变破坏了用不同软件在SERPINC1中鉴定出的五个潜在维生素D受体元件(VDRE)中的两个。一种基因缺陷,即c.42-1060_-1057dupTTGA,是一种新的低频率多态性(MAF:0.01),对血浆抗凝血酶水平有功能影响。维生素D途径对SERPINC1调控的相关性在细胞模型中得到了证实。用维生素D类似物帕立骨化醇孵育HepG2细胞,可使SERPINC1转录本水平和释放到条件培养基中的抗凝血酶水平呈剂量依赖性增加。本研究进一步证明了维生素D对SERPINC1的转录调控,并首次描述了影响该基因VDRE的突变的功能和病理相关性。我们的研究为寻找与抗凝血酶缺乏和血栓形成风险相关的新基因缺陷以及设计新的抗血栓治疗方法开辟了新的前景。